Summary
A major impediment to the successful use of Taxol in the treatment of cancer is the development of drug resistance. The major cellular target of Taxol is the microtubule that is comprised of α- and β-tubulin heterodimers. Binding sites for Taxol have been delineated on the β-tubulin subunit that has six isotypes. We have recently described increased expression of the brain-specific human class III β-tubulin isotype, encoded by the Hβ4 gene, in both Taxol-resistant ovarian tumours and non-small-cell lung cancer cell lines. To evaluate directly the role of the class III β-tubulin isotype in mediating Taxol resistance, antisense phosphorothioate oligodeoxynucleotides (ODN) targeted against various regions of the Hβ4 gene have been designed and examined for their efficacy in reducing Hβ4 gene and protein expression. Taxol-resistant lung cancer cells, A549-T24, which are 17-fold resistant to Taxol and display a fourfold increase in Hβ4 expression compared to the parental A549 cells, were treated with 1 μM antisense ODNs. Two ODNs, AS1 and AS3, were found to reduce mRNA expression by 40–50%, as determined by reverse transcription polymerase chain reaction. A concentration-dependent reduction in Hβ4 mRNA expression was demonstrated with AS1 ODN. Immunofluorescence staining of cells treated with AS1 ODN revealed a decrease in class III protein expression which corresponded to a 39% increase in sensitivity to Taxol (P < 0.005). These findings support an important role for Hβ4 (class III) β-tubulin expression in Taxol resistance and have potential implications for the treatment of Taxol-resistant tumours.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Akhtar, S. & Juliano, R. L. (1992). Cellular uptake and intracellular fate of antisense oligonucleotides. Trends Cell Biol 2: 139–143.
Alahari, S. K., Dean, N. M., Fisher, M. H., Delong, R., Manoharan, M., Tivel, K. L. & Juliano, R. L. (1996). Inhibition of expression of the multidrug resistance-associated P-glycoprotein by phosphorothioate antisense oligonucleotides. Mol Pharmacol 50: 808–819.
Banerjee, A., Roach, M. C., Trcka, P. & Luduena, R. F. (1990). Increased microtubule assembly in bovine brain tubulin lacking the type III isotype of β-tubulin. J Biol Chem 165: 1794–1799.
Derry, W. B., Wilson, S., Khan, I. A., Luduena, R. F. & Jordan, M. A. (1997). Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified β-tubulin isotypes. Biochemistry 36: 3554–3562.
Dumontet, C., Duran, G. E., Steger, K. A., Beketic-Oreskovic, L. & Sikic, B. I. (1996). Resistance mechanisms in human sarcoma mutants derived by single-step exposure to Paclitaxel (taxol). Cancer Res 56: 1091–1097.
Giannakakou, P., Sackett, D. L., Kang, Y. K., Zhan, Z., Buters, J. T., Fojo, T. & Poruchynsky, M. S. (1997). Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272: 17118–17125.
Gonzalez-Garay, M. L. & Cabral, F. (1995). Overexpression of an epitope-tagged β-tubulin in chinese hamster ovary cells causes an increase in endogenous α-tubulin synthesis. Cell Motil Cytoskel 31: 259–272.
Haber, M., Burkhart, C. A., Regl, D. L., Madafiglio, J., Norris, M. D. & Horwitz, S. B. (1995). Altered expression of Mβ2, the class II β-tubulin isotype, in a murine J744.2 cell line with a high level of taxol resistance. J Biol Chem 270: 31269–31275.
Helene, C. & Toulme, J. J. (1990). Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta 1049: 99–125.
Horwitz, S. B., Cohen, D., Rao, S., Ringel, I., Shen, H. J. & Yang, C. P. (1993). Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr 15: 55–61.
Hyams, J. S. & Lloyd, C. W. (1994). Microtubules. Wiley-Liss: New York
Jaffrezou, J-P, Dumontet, C., Derry, W. B., Duran, G., Chen, G., Tsuchiya, E., Wilson, L., Jordan, M. A. & Sikic, B. L. (1995). Novel mechanism of resistance to Paclitaxel (Taxol®) in human K562 leukemia cells by combined selection with PSC 833. Oncol Res 7: 517–527.
Jordan, M. A. & Wilson, L. (1998). Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 10: 123–130.
Kavallaris, M., Kuo, DY-S, Burkhart, C. A., Regl, D. L., Norris, M. D., Haber, M. & Horwitz, S. B. (1997). Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J Clin Invest 100: 1282–1293.
Lewis, S. A. & Cowan, N. J. (1990). Tubulin genes: structure, expression, and regulation. In Microtubule Proteins, Avila J (ed), pp. 37–66. CRC Press, Inc.: Boca Raton, Florida
Lu, Q. & Luduena, R. F. (1993). Removal of βIII isotype enhances taxol induced microtubule assembly. Cell Struct Funct 18: 173–182.
Luduena, R. F. (1998). Multiple forms of tubulin: different gene products and covalent modifications. Int Rev Cytol 178: 207–274.
Mitchison, T. J. & Kirschner, M. W. (1984). Dynamic instability of microtubule growth. Nature 312: 237–242.
Panda, D., Miller, H. P., Banerjee, A., Luduena, R. F. & Wilson, L. (1994). Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci 91: 11358–11362.
Ranganathan, S., Dexter, D. W., Benetatos, C. A., Chapman, A. E., Tew, K. D. & Hudes, G. R. (1996). Increase of βIII- and βIVa-tubulin in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res 56: 2584–2589.
Ranganathan, S., Benetatos, C. A., Colarusso, P. J., Dexter, D. W. & Hudes, G. R. (1998a). Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 77: 562–566.
Ranganathan, S., Dexter, D. W., Benetatos, C. A. & des, G. R. (1998b). Cloning and sequencing of human betaIII-tubulin cDNA: induction of betaIII isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents. Biochem Biophys Acta 1395: 237–245.
Rao, S., Orr, G. A., Chaudhary, A. G., Kingston, D. G. I. & Horwitz, S. B. (1995). Characterization of the taxol binding site on the microtubule. J Biol Chem 270: 20235–20238.
Stewart, A. J., Canitrot, Y., Baracchini, E., Dean, N. M., Deeley, R. G. & Cole, S. P. C. (1996). Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides. Biochem Pharmacol 51: 461–469.
Sullivan, K. F. & Cleveland, D. W. (1986). Identification of conserved isotype-defining variable region sequences for four vertebrate β tubulin polypeptide classes. Proc Natl Acad Sci USA 83: 4327–4331.
Wagner, R. W. (1994). Gene inhibition using antisense oligonucleotides. Nature 372: 333–335.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Kavallaris, M., Burkhart, C. & Horwitz, S. Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer 80, 1020–1025 (1999). https://doi.org/10.1038/sj.bjc.6690507
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690507
Keywords
This article is cited by
-
Collateral responses to classical cytotoxic chemotherapies are heterogeneous and sensitivities are sparse
Scientific Reports (2022)
-
CTCs-oriented adjuvant personalized cytostatic therapy non-metastatic breast cancer patients: continuous non-randomized prospective study and prospective randomized controlled study
Breast Cancer Research and Treatment (2021)
-
CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells
Investigational New Drugs (2020)
-
LncRNA RPPH1 promotes colorectal cancer metastasis by interacting with TUBB3 and by promoting exosomes-mediated macrophage M2 polarization
Cell Death & Disease (2019)
-
Aurora B expression modulates paclitaxel response in non-small cell lung cancer
British Journal of Cancer (2017)